MPGN type I induced by granulocyte colony stimulating factor

Daniella Magen; Hana Mandel; Moshe Berant; Ofer Ben-Izhak; Israel Zelikovic

doi:10.1007/s00467-002-0847-9

MPGN type I induced by granulocyte colony stimulating factor

Pediatr Nephrol. 2002 May;17(5):370-2. doi: 10.1007/s00467-002-0847-9.

Authors

Daniella Magen¹, Hana Mandel, Moshe Berant, Ofer Ben-Izhak, Israel Zelikovic

Affiliation

¹ Pediatric Nephrology Unit, Rambam Medical Center, P.O. Box 9602, Haifa 31096, Israel. [email protected]

PMID: 12042897
DOI: 10.1007/s00467-002-0847-9

Abstract

We report a girl with severe congenital neutropenia who has received long-term granulocyte-colony stimulating factor (G-CSF) therapy and has developed macroscopic hematuria, proteinuria, and decreased renal function associated with biopsy-proven membranoproliferative glomerulonephritis (MPGN) type I. Temporary discontinuation of G-CSF therapy as well as the use of glycosylated G-CSF has resulted in improvement in renal manifestations. We postulate that the MPGN was G-CSF-induced. Long-term G-CSF therapy should be used with great caution and close surveillance of kidney function.

Publication types

Case Reports

MeSH terms

Adjuvants, Immunologic / therapeutic use
Adolescent
Drug Administration Schedule
Female
Glomerulonephritis, Membranoproliferative / chemically induced*
Glomerulonephritis, Membranoproliferative / pathology
Granulocyte Colony-Stimulating Factor / administration & dosage
Granulocyte Colony-Stimulating Factor / adverse effects*
Granulocyte Colony-Stimulating Factor / therapeutic use
Humans
Lenograstim
Neutropenia / congenital
Neutropenia / drug therapy
Recombinant Proteins / therapeutic use
Retreatment

Substances

Adjuvants, Immunologic
Recombinant Proteins
Granulocyte Colony-Stimulating Factor
Lenograstim